Key points are not available for this paper at this time.
This JAMA Insights Clinical Update reviews the central role of apolipoprotein B100 molecule (apoB)–containing lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD), with implications for patient risk assessment and choice of lipid-lowering therapy.
Ference et al. (Wed,) studied this question.